IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer (NSCLC)
NSCLC (Non-small-cell Lung Cancer)
DRUG: Sintilimab|DRUG: IBI310
Objective Response Rate(ORR), Investigator evaluated ORR per RECIST V1.1, Up to 2 years|Treatment Emergent Adverse Event (TEAE), Incidence and severity of treatment-emergent: which is evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v5.0) grade;, Up to 2 years|Severe Adverse Event (SAE), Incidence and severity of treatment-emergent: which is evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v5.0) grade;, Up to 2 years
DOR, Defined as the time from the first documented objective response to the first documented progressive disease or death of any cause, whichever occurs first;, Up to 2 years|Progression Free Survival (PFS), Defined as the time from randomization to the first documented progressive disease or death of any cause, whichever occurs first;, Up to 2 years|Overall Survival (OS), Defined as the time from randomization to death of any cause in subjects without receiving any immunotherapy outside the study protocol for first-line treatment of advanced NSCLC, Up to 2 years|Disease Control Rate (DCR), Defined as the proportion of patients whose best response is CR, PR, and stable disease (SD) non-CR/non-PD, Up to 2 years|Time to Response (TTR), Defined as the time from randomization to the first documented and confirmed objective response (CR or PR), Up to 2 years|HRQoL, According to EORTC QLQ-C30, Up to 2 years
This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer (NSCLC)